PA3-17 cell therapy for relapsed/refractory T-cell blood cancers in children
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new cell therapy called PA3-17 in children and teens (ages 3–18) whose T-cell leukemia or lymphoma has come back or stopped responding to standard treatment. The goal is to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 3–18 years old
- Diagnosed with T-ALL or T-LBL (T-cell blood cancer) that has relapsed (come back) or is refractory (not responding to treatment)
- Good overall health status (doctor will assess using a standard scoring system)
- Normal or near-normal liver, kidney, heart, and lung function
- Cancer cells must have CD7 marker detectable in blood, bone marrow, or tumor tissue
- Never received CAR-T or other gene-modified cell therapies before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called PA3-17, which uses your own immune cells modified to target and kill cancer cells that have a protein called CD7 on them. It is designed for patients with T-cell leukemia or lymphoma that has come back or did not respond to prior treatments.
This trial tests a new CAR T-cell therapy (called RD06-03) for people whose B-cell acute lymphoblastic leukemia (B-ALL) has returned or hasn't responded to other treatments. It aims to see if the therapy is safe and can help fight the leukemia.
This trial tests a new cell therapy (QH103) for people with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. The therapy uses specially modified immune cells to find and kill cancer cells that have a protein called CD19 on their surface.
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
This trial tests a new cell therapy called CD7 CAR-T for children with high-risk T-cell lymphoblastic leukemia or lymphoma who have finished initial chemotherapy and are in remission. It aims to prevent relapse.
This trial tests a new type of immunotherapy called anti-CD7 CAR-T cells for children and young adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to see if these specially engineered immune cells can find and destroy cancer cells that carry the CD7 protein.
Hear when a new CD7+ T-ALL/LBL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.